leisure time -WSS

leisure time

author：entertainment 2025-09-02 08:19:53 - browse：9

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Alabama hospital puts IVF treatments on hold

focus

WSS

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

With competition flaring, obesity drug hits goal in liver disease study

Obesity drugs seen as possible treatment for liver disease MASH

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

#NeedHerScience: shining a light on gender disparities in medicine

Ask STAT: What do you want to know about ChatGPT in medicine?

hotspot

leisure time

explore

Trump demands the U.S. pay no more for drugs than other countries … again

In utero gene editing: an explainer

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

In areas with more Black doctors, Black people live longer

United colonoscopy coverage change 'may cost lives,' doctors say

With FDA staff opposed to Sarepta therapy, top official intervened

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Colonoscopy at 40? Study finds a possible benefit

Medical leaders decry Supreme Court decision on affirmative action

Weight bias in eating disorder treatment complicated by new weight loss drugs

knowledge

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

WATCH: Why do fingernails fall off when they're damaged?

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

focus

focus

entertainment

focus